Peripheral T-cell lymphoma

Common Name(s)

Peripheral T-cell lymphoma

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Peripheral T-cell lymphoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Peripheral T-cell lymphoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Peripheral T-cell lymphoma" returned 236 free, full-text research articles on human participants. First 3 results:

E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study.
 

Author(s): Ken Ohmachi, Kiyoshi Ando, Michinori Ogura, Toshiki Uchida, Kensei Tobinai, Dai Maruyama, Masayuki Namiki, Tadashi Nakanishi

Journal: Cancer Sci.. 2018 Mar;109(3):794-802.

 

E7777, a recombinant cytotoxic fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2, shares an amino acid sequence with denileukin diftitox but has improved purity and an increased percentage of active protein monomer species. A phase I study was carried ...

Last Updated: 31 Dec 1969

Go To URL
Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment.
 

Author(s): Hiroaki Tanaka, Hanako Aoki, Yasumasa Sugita, Ryo Shimizu, Katsunari Kiko, Hidetoshi Mochida, Yoshio Suzuki

Journal: Intern. Med.. 2017 Oct;56(20):2759-2763.

 

Mogamulizumab is a defucosylated humanized anti-CC chemokine receptor type 4 (CCR4) antibody that exerts an anti-tumor immune effect against various tumors through a suppressive effect on regulatory T-cells. We herein report a patient with peripheral T-cell lymphoma who developed ...

Last Updated: 31 Dec 1969

Go To URL
Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
 

Author(s): Dai Maruyama, Hirokazu Nagai, Yoshinobu Maeda, Takahiko Nakane, Tatsu Shimoyama, Tomonori Nakazato, Rika Sakai, Takayuki Ishikawa, Koji Izutsu, Ryuzo Ueda, Kensei Tobinai

Journal: Cancer Sci.. 2017 Oct;108(10):2061-2068.

 

Pralatrexate is a novel antifolate approved in the USA for the treatment of relapsed or refractory peripheral T-cell lymphoma. To assess its safety, efficacy, and pharmacokinetics in Japanese patients with this disease, we undertook a phase I/II study. Pralatrexate was given i.v. ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Peripheral T-cell lymphoma" returned 26 free, full-text review articles on human participants. First 3 results:

Peripheral T-cell lymphoma, not otherwise specified.
 

Author(s): Alessandro Broccoli, Pier Luigi Zinzani

Journal: Blood. 2017 03;129(9):1103-1112.

 

Peripheral T-cell lymphoma, not otherwise specified, is a broad category of biologically and clinically heterogeneous diseases that cannot be further classified into any other of the existing entities defined by the World Health Organization classification. Anthracycline-containing ...

Last Updated: 31 Dec 1969

Go To URL
Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review.
 

Author(s): Ya-Ting Yang, Cheng-Jeng Tai, Chiehfeng Chen, Hong-Cheng Wu, Natalia Mikhaylichenko, Hsien-Tsai Chiu, Yun-Yi Chen, Yi-Hsin Elsa Hsu

Journal:

 

The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL.

Last Updated: 31 Dec 1969

Go To URL
Therapeutic options in peripheral T cell lymphoma.
 

Author(s): Yaping Zhang, Wei Xu, Hong Liu, Jianyong Li

Journal:

 

Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. The standard first-line treatments have resulted in unsatisfactory patient outcomes. With the exception of low-risk anaplastic lymphoma kinase (ALK)-positive anaplastic ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients
 

Status: Not yet recruiting

Condition Summary: Peripheral T Cell Lymphoma

 

Last Updated: 13 Jan 2017

Go to URL
Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
 

Status: Recruiting

Condition Summary: Peripheral T-cell Lymphoma

 

Last Updated: 23 Oct 2017

Go to URL
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients
 

Status: Recruiting

Condition Summary: Peripheral T-cell Lymphoma

 

Last Updated: 20 Jul 2017

Go to URL